Last updated: 2026-09-09 08:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Zenas BioPharma, Inc. (ZBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $33.08, with a market capitalization of $2.14B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.50 to $44.60. This page covers its latest market performance, valuation, price trends and company information.
$2.14B | |
$32.65 | |
$101.90 | |
$5.83 | |
$32.88 | |
382.78K | |
846.19K | |
-- | |
$44.60 | |
$13.50 | |
-- | |
-- |
Zenas BioPharma, Inc. (ZBIO) is trading at $32.93 in pre-market trading as of 2026-09-08 23:45:00, up 0.14% ($0.04) from the previous close of $32.88
Pre-market trading shows how investors are pricing ZBIO before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Zenas BioPharma, Inc. (ZBIO) moved from $31.27 to $33.08, representing a gain of 5.79% ($1.81).
The stock traded between $29.88 and $33.84 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 509.37 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 63.0%
ZBIO is currently trading at $33.08, placing it 63.0% of the way from its 52-week low of $13.50 to its 52-week high of $44.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 167 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zenas BioPharma, Inc. (ZBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.